Published in J Clin Oncol on June 01, 1992
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J (1996) 5.14
Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog (2006) 3.65
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res (2000) 2.13
NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer (2008) 1.82
RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia (2001) 1.63
Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer (2010) 1.54
WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res (2004) 1.51
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia (2004) 1.35
Update on inflammatory breast cancer. Breast Cancer Res (2005) 1.29
Inflammatory breast cancer: clinical progress and the main problems that must be addressed. Breast Cancer Res (2003) 1.28
Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One (2010) 1.26
RUNX1 and its understudied role in breast cancer. Cell Cycle (2011) 1.16
Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat (2007) 1.11
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin Exp Metastasis (2002) 1.10
c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays. Br J Cancer (2007) 0.98
EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer Res (2013) 0.96
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer (1999) 0.96
Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer (2008) 0.94
p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer (1994) 0.91
Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer. Breast Cancer Res Treat (2011) 0.91
Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS One (2012) 0.90
Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat (2015) 0.90
In vivo lymphatic imaging of a human inflammatory breast cancer model. J Cancer (2014) 0.86
Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium. J Thorac Dis (2010) 0.86
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res (2013) 0.86
The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin Exp Metastasis (2006) 0.84
Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas. Proc (Bayl Univ Med Cent) (2011) 0.84
Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer (2002) 0.83
Cytotoxic and Antitumor Activity of Sulforaphane: The Role of Reactive Oxygen Species. Biomed Res Int (2015) 0.81
Inflammatory breast cancer: New factors contribute to disease etiology: A review. J Adv Res (2013) 0.81
On how CCN6 suppresses breast cancer growth and invasion. J Cell Commun Signal (2011) 0.80
Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J (2009) 0.80
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res (2014) 0.78
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer. J Cancer Res Clin Oncol (2010) 0.78
Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancer. Oncotarget (2016) 0.78
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget (2016) 0.77
Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis. Oncotarget (2016) 0.77
Differential effects of vitamin D treatment on inflammatory and non-inflammatory breast cancer cell lines. Clin Exp Metastasis (2012) 0.76
Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One (2016) 0.76
DNA Damage Response and Immune Defense: Links and Mechanisms. Front Genet (2016) 0.75
Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature. Oncol Lett (2016) 0.75
Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. J Natl Cancer Inst (2015) 0.75
Osteoprotegerin rich tumor microenvironment: implications in breast cancer. Oncotarget (2016) 0.75
Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. Springerplus (2014) 0.75
Diverse presentations of carcinoma erysipelatoides from a teaching hospital in australia. Case Rep Dermatol Med (2012) 0.75
Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers. Oncotarget (2017) 0.75
Survival after surgical treatment of breast cancer. Langenbecks Arch Surg (2004) 0.75
EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget (2017) 0.75
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol (1999) 7.59
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet (2000) 3.25
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Pathol (1990) 2.88
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol (2014) 2.50
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol (1997) 2.36
Carcinoma of the male breast. Ann Intern Med (1992) 2.27
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol (1996) 2.27
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol (2000) 2.19
Multimodal treatment for inflammatory breast cancer. Int J Radiat Oncol Biol Phys (1989) 2.09
Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol (1995) 2.08
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer (1988) 1.79
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am (1998) 1.77
Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer (1998) 1.71
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer. Ann Intern Med (1994) 1.66
Early and delayed clinical cardiotoxicity of doxorubicin. Cancer (1985) 1.61
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg (1999) 1.60
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol (1998) 1.58
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer (2001) 1.57
Estrogen receptor: a prognostic factor in breast cancer. Cancer (1981) 1.51
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer. Cancer J Sci Am (1999) 1.48
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up. Ann Oncol (2000) 1.46
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res (1997) 1.43
The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg (1989) 1.41
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg (1998) 1.40
Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology (1988) 1.38
Causes of death in breast cancer: a clinicopathologic study. Cancer (1980) 1.34
Clinical course of breast cancer patients with liver metastases. J Clin Oncol (1987) 1.32
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (2001) 1.28
Multimodal treatment of locoregionally advanced breast cancer. Cancer (1983) 1.26
Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat (2000) 1.24
Inflammatory breast cancer and body mass index. J Clin Oncol (1998) 1.21
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer (1999) 1.19
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist (2001) 1.17
Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol (1999) 1.13
Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol (1997) 1.12
Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol (2000) 1.12
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol (1996) 1.10
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2000) 1.09
Improved culture conditions for clonogenic growth of primary human breast tumours. Br J Cancer (1984) 1.09
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol (2008) 1.07
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg (2001) 1.06
Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. Cancer Res (1997) 1.05
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. Am J Surg (2000) 1.05
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer (2000) 1.05
Role of adjuvant chemotherapy in male breast cancer. Cancer (1989) 1.04
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep (1979) 1.03
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat (1982) 1.03
Present status of anthracyclines in the adjuvant treatment of breast cancer. Drugs (1993) 1.02
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol (1997) 1.01
Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr (1986) 1.01
Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer (1985) 1.01
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer (1990) 1.01
Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res (2001) 1.00
Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr (1986) 1.00
Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer (1986) 1.00
Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification. J Clin Oncol (1989) 1.00
High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol (1987) 1.00
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer (1981) 0.99
Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf (2000) 0.99
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol (1987) 0.98
Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep (1979) 0.98
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol (1996) 0.98
Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med (1979) 0.98
Hormonal therapy for metastatic male breast cancer. Arch Intern Med (1983) 0.97
Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol (1999) 0.97
Tamoxifen-induced hypercalcemia in breast cancer. Cancer (1981) 0.97
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol (2001) 0.96
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer (1989) 0.96
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol (2013) 0.96
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med (1996) 0.96
Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. AJR Am J Roentgenol (2000) 0.96
Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med (1981) 0.95
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol (2007) 0.95
Breast cancer and second primary ovarian cancer in dermatomyositis. Gynecol Oncol (1991) 0.95
Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer (1978) 0.95
Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. J Clin Oncol (1989) 0.95
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. Clin Transplant (2000) 0.95
Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA (1983) 0.95
Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol (1986) 0.95
Endobronchial metastases in breast carcinoma. West J Med (1978) 0.94
Markers of bone resorption in patients treated with pamidronate. Eur J Cancer (1998) 0.94
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med (1996) 0.94
c-erbB-2 amplification in node-negative human breast cancer. Cancer Res (1989) 0.94
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA (1979) 0.94
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol (2001) 0.93
Pregnancy and breast cancer: clinical and legal issues. Am J Clin Oncol (1992) 0.92
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys (2000) 0.92
5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer (1989) 0.92
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J (2001) 0.92
Hematologic adverse effects of aminoglutethimide. Ann Intern Med (1984) 0.92